AbbVie (ABBV) rebounds after losses, gaining ~% as analysts stay bullish. Discover why its obesity drug deal boosts long-term ...

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...

Since the announcement in early March, AbbVie stock reached an all-time high at over $216 per share. The stock has fallen ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) Q4 2024 Earnings Call Transcript March 26, 2025 CollPlant Biotechnologies Ltd.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...